21.06.2021 CytoTools AG  DE000A0KFRJ1

DGAP-News: CytoTools Q1 Trading Update: Treatment numbers in India slightly above previous quarter despite significant pandemic impact


DGAP-News: CytoTools AG / Key word(s): Quarter Results/Market launch
CytoTools Q1 Trading Update: Treatment numbers in India slightly above previous quarter despite significant pandemic impact

21.06.2021 / 09:30
The issuer is solely responsible for the content of this announcement.

CytoTools Q1 Trading Update: Treatment numbers in India slightly above previous quarter despite significant pandemic impact

- Over 10,000 use cases in Q1 despite tough lockdown in India
- Expansion into Africa following provisional approval of Woxheal in Kenya

Darmstadt, 21 June 2021 - CytoTools AG (ISIN DE000A0KFRJ1), a biotechnology holding company specializing in pharmaceutical and medical products, has received a trading update on the first quarter of 2021 from its licensing partner Centaur Pharmaceuticals on the drug Woxheal(R) for the treatment of the Diabetic Foot Syndrome. According to the update, despite significant pandemic-related sales hinderances, sales of Woxheal(R) in India have increased slightly to over 10,000 use cases compared to the fourth quarter of 2020.

"Of course, it still has to be said that these figures are still significantly below our expectations and the expectations of our license partner," underlines Dr. Mark-André Freyberg, CEO of CytoTools. "At the same time, however, the figures show that the treating physicians are convinced of the drug, continue to prescribe it and that the active ingredient is achieving very good treatment results as expected." Based on current significantly declining COVID-19 incidence numbers in India, the company is confident that the number of treatments can increase noticeably in the second half of 2021 and that the roll-out of the product will be accelerated as originally planned.

In addition, Centaur Pharmaceuticals has informed the Company that it has now received tentative approval for Woxheal(R) in Kenya, Africa. Provisional approval of a drug can be granted in Kenya without additional studies based on the approval of the India Central Drugs Standard Control Organization (CDSCO). In parallel, Centaur is seeking approval for the drug in other African countries where a basically similar approval process is possible. "We would also like to emphasize for this market that we have to assume a very subdued marketing start against the background of COVID-19 and our experience from India," emphasizes Dr. Dirk Kaiser, Board Member for Research & Development at CytoTools. "Nevertheless, we regard this step as very positive, as it underpins the high value that is attached to the active ingredient DPOCL in other countries as well. It underlines the high relevance of the approval in India internationally and we assess the chances of a successful outcome of the clinical phase III in Europe as still very high." CytoTools initiated Phase III clinical trials of its DPOCL compound in Europe in the first quarter of 2021. Despite delays due to the progress of COVID-19 in Europe, the Management Board assesses the current progress of the study as still on track. Therefore, the company still expects to be able to report interim results of the study at the end of 2021 and then to successfully complete Phase III by the end of 2022.

Against the background of the marketing delays in India triggered by COVID-19, the Management Board of CytoTools AG, in consultation with the Supervisory Board, has decided to reduce the size of the Board of Directors again from three to two members and to divide the responsibilities of the Chief Financial Officer Marc Herwick between the two other members of the Board of Directors. "We created the position of Chief Financial Officer largely against the background of a rapid roll-out of Woxheal in India. However, in the current environment, this clearly seems premature," explains CEO Dr. Mark-André Freyberg. "Although we continue to be well financed, we keep close control on the budget and want to use our liquidity in a targeted manner for the further development of our operating business. Therefore, we have reached a mutual agreement with Mr. Herwick to terminate our cooperation. We thank him for his efforts for the company and wish him all the best personally and professionally."

Additional information about CytoTools AG, its affiliated subsidiaries and the holding company's drug pipeline is available on the company's website at www.cytotools.de.

CytoTools AG
Ingo Middelmenne
Investor Relations
Mobile: +49-174-9091190
Email: [email protected]

About CytoTools:
CytoTools AG is a German biotechnology holding company that translates results from basic cell biology research on cell growth and programmed cell death into novel therapies for causal disease treatment and cure. CytoTools' versatile product pipeline includes proprietary chemical compounds and biopharmaceuticals that have the potential to provide new treatment options in dermatology, cardiology, urology and oncology. CytoTools is structured as a technology holding and investment company and holds interests in its subsidiaries DermaTools Biotech GmbH (65%) and CytoPharma GmbH (50%).


This release contains certain forward-looking statements. These reflect the views of CytoTools as of the date of this release. Actual results achieved by CytoTools may differ materially from the findings in the forward-looking statements. CytoTools is under no obligation to update any forward-looking statements.

21.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: CytoTools AG
Klappacher Str. 126
64285 Darmstadt
Phone: +49 (0)6151-951 58 12
Fax: +49 (0)6151-951 58 13
E-mail: [email protected]
Internet: www.cytotools.de
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1210083

End of News DGAP News Service

1210083  21.06.2021 


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023
Umsatzerlöse1 0,09 0,00 0,04 0,85 0,04 0,01 0,00
EBITDA1,2 -1,16 -0,92 -1,16 -3,00 -1,47 -0,82 0,00
EBITDA-Marge3 -1.288,89 0,00 -2.900,00 -352,94 -3.675,00 -8.200,00
EBIT1,4 -1,12 -1,22 -1,17 -3,10 -4,01 -0,82 0,00
EBIT-Marge5 -1.244,44 0,00 -2.925,00 -364,71 -10.025,00 -8.200,00 0,00
Jahresüberschuss1 -1,07 -1,42 -1,28 -3,30 -4,06 -0,83 0,00
Netto-Marge6 -1.188,89 0,00 -3.200,00 -388,24 -10.150,00 -8.300,00 0,00
Cashflow1,7 -1,15 -1,39 -1,26 -1,66 -1,56 -0,91 0,00
Ergebnis je Aktie8 -0,51 -0,53 -0,35 -0,46 -1,01 -0,16 -4,00
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Nexia

WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0KFRJ 0,426 Verkaufen 2,19
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,00 -0,93
1,46 - 182,38 -2,68
Dividende '22 in € Dividende '23 in € Div.-Rendite '23
in %
0,00 0,00 0,00 04.08.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
- 03.07.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-11,80% -36,42% -4,48% -78,70%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu CytoTools AG  ISIN: DE000A0KFRJ1 können Sie bei EQS abrufen

Biotechnologie , A0KFRJ , T5O , XETR:T5O